Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Matias says precision neuroscience is limited by messy, non-normalized data and by a missing business model. Wearables and other data exist, but few multidisciplinary teams turn them into a source of truth or deploy them with aligned incentives. He lists these practical gaps alongside the brain's underlying complexity.

Related Insights

Matias says his time at NVIDIA gave him an insider view of AI progress—more compute, better data, better models—converging with neurobiology. That visibility helped convince him a venture fund focused on brain and mental health could work. He calls it one of the lucky breaks behind SciMed's launch.

The biggest limitation in precision medicine is the systemic failure to capture and learn from longitudinal data on how patients respond to treatments over time. Without this critical feedback loop, even the most sophisticated diagnostic models will fall short of their potential to improve care.

Advanced AI models are ineffective in clinical settings without a robust data layer. Ambience had to solve fundamental problems like pulling messy context from inconsistent EHRs and preserving 'decision traces,' which are often destroyed by existing systems with mutable data structures.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

The bottleneck for AI in drug discovery is not the algorithm but the lack of high-quality, large-scale biological data. New platforms are needed to generate this necessary "substrate" for AI models to learn from, challenging the narrative that better models alone are the solution.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

While AI excels where large, clean datasets exist (like protein folding), it struggles with modeling slow, progressive diseases like Alzheimer's or obesity. These are organ-level phenomena, and the necessary data doesn't exist yet. In vivo platforms are critical for generating this required foundational data.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.

Advanced health tech faces a fundamental problem: a lack of baseline data for what constitutes "optimal" health versus merely "not diseased." We can identify deficiencies but lack robust, ethnically diverse databases defining what "great" health looks like, creating a "North Star" problem for personalization algorithms.

Guardant's co-CEO is skeptical of many AI-in-biology efforts because the underlying public data is often 'very under sampled.' These low-resolution datasets miss the rare signals that differentiate cells, causing AI models to learn from noise rather than true biological drivers of disease.

Precision neuroscience is blocked by data and business models. | RiffOn